Did Abbott raise its 2026 guidance?

Yes, the company raised its full-year EPS guidance based on strong Q2 performance.

Which segments drove Abbott's growth?

Nutrition, Medical Devices, and Emerging Markets were the key growth drivers.

How will ABT stock be affected by these results?

The stock is expected to be positively impacted due to the raised guidance and strong performance.

Abbott Laboratories Raises 2026 EPS Guidance After Strong Q2 Results

Abbott Laboratories (ABT) reported strong Q2 2026 results, driven by robust growth in Nutrition, Medical Devices, and Emerging Markets. The company raised its full-year EPS guidance based on the solid performance.

July 16, 2026

2 min read

Source: GuruFocus.com

Key Numbers

revenue

not disclosed

eps

raised

segment growth

strong

Abbott Laboratories (ABT) reported robust sales growth for the second quarter of 2026, driven by strong performance in its Nutrition, Medical Devices, and Emerging Markets segments. As a result, the company raised its full-year earnings per share (EPS) guidance.

Key Financial Results

Metric	Q2 2026	YoY Change
Revenue	Not disclosed	Strong growth
Net Income	Not disclosed	Positive
EPS	Guidance raised	Expected to beat estimates

Highlights from the Call

Nutrition: Strong growth driven by increased demand for specialized nutrition products.
Medical Devices: Continued strong performance supported by new innovations.
Emerging Markets: Significant contribution to revenue growth.

Guidance

Abbott raised its full-year 2026 EPS guidance, reflecting management's confidence in sustained momentum.

Impact on Stock

The announcement is expected to positively impact ABT shares, as raised guidance signals strong business health.

What This Means for Investors

Abbott's results demonstrate the strength of its diversified business model, particularly in Nutrition and Medical Devices. The raised guidance reinforces confidence in the company's ability to deliver sustainable growth.

Frequently Asked Questions

Abbott reported strong sales growth driven by Nutrition, Medical Devices, and Emerging Markets, and raised its full-year EPS guidance.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.